Merck & Co Inc Stock (MRK) Moved Up by 3.24% on Mar 25: Drivers Behind the Movement

MRK's stock experienced an upward movement due to a significant corporate development. The company announced today its definitive agreement to acquire Terns Pharmaceuticals, Inc. for approximately $6.7 billion in cash. This acquisition is a strategic move to bolster Merck's oncology pipeline, particularly as it prepares for the impending patent expiration of its blockbuster cancer drug, Keytruda, later this decade.

The centerpiece of this acquisition is Terns' lead candidate, TERN-701, an investigational oral drug for chronic myeloid leukemia (CML). TERN-701 has shown promising activity in early-stage clinical trials, demonstrating encouraging rates of major molecular response and deep molecular response in previously treated patients. Analysts suggest that TERN-701 has the potential to become a significantly differentiated option for CML patients and could challenge existing treatments in the market. This deal is viewed as a proactive step by Merck to diversify its revenue streams and maintain growth beyond Keytruda's loss of exclusivity.

Merck's continued aggressive M&A strategy, including previous acquisitions, highlights its commitment to building a robust pipeline across oncology and other therapeutic areas. This focus on pipeline-driven resilience is a key factor in the positive market reaction, as investors see the company actively addressing future revenue challenges. Although the deal will result in an approximate $5.8 billion charge, or $2.35 per share, in the second quarter and full-year 2026 GAAP and non-GAAP results, the long-term strategic benefits appear to outweigh the short-term accounting impact in the eyes of the market.

Technically, Merck & Co Inc (MRK) shows a MACD (12,26,9) value of [-0.13], indicating a sell signal. The RSI at 49.46 suggests neutral condition and the Williams %R at -46.36 suggests oversold condition. Please monitor closely.

In terms of media coverage, Merck & Co Inc (MRK) shows a coverage score of 49, indicating a moderate level of media attention. The overall market sentiment index is currently in bullish zone.

Merck & Co Inc (MRK) is in the Pharmaceuticals & Medical Research industry. Its latest annual revenue is $65.01B, ranking 5 in the industry. The net profit is $18.25B, ranking 3 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Buy, with an average price target of $127.84, a high of $150.00, and a low of $95.00.

Company Specific Risks:

• The recently announced $6.7 billion acquisition of Terns Pharmaceuticals will result in a significant charge of approximately $5.8 billion, or $2.35 per share, impacting Merck's Q2 and full-year 2026 GAAP and non-GAAP financial results.
• Merck anticipates a substantial decline in sales for its diabetes drugs, Januvia and Janumet, as they face loss of exclusivity with generic versions expected to launch after May 2026.
• Ongoing strategic pressure to diversify and acquire new pipeline assets, evidenced by the Terns acquisition, is driven by the significant revenue risk associated with the impending U.S. patent expiry of Keytruda, which contributes an estimated 40% of the company's pharmaceutical revenues.
• Analyst concerns persist regarding potential "modest growth" and operational challenges, stemming from a reported 35% decline in Gardasil sales in China and Japan and 2026 sales guidance that fell below consensus estimates.